QIAGEN Reports Results for Second Quarter of 2016; Increased Commitment to Return $300 Million of Capital to Shareholders by End-2017

VENLO, The Netherlands, July 28, 2016

• Q2 2016 results show QIAGEN delivering on goals for acceleration during the year 
  • Net sales of $334.4 million (+5% actual, +6% constant exchange rates, CER);
    EPS of $0.09; adjusted EPS of $0.24 ($0.24 CER) 
  • 8% CER sales growth excluding impact from lower U.S. HPV test sales 
  • Free cash flow up 75% to $77.6 million 
• Sample to Insight portfolio transformation gaining momentum on improving trends among customers in Life Sciences and Molecular Diagnostics  
• QIAGEN on track for continued acceleration in H2 2016 and achieving targets for full-year 2016 growth in net sales and adjusted EPS 
• Increased commitment to return $300 million to shareholders by end of 2017  

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the second quarter and first half of 2016, delivering on goals for net sales and adjusted earnings per share results while updating full-year 2016 targets for the acquisition of Exiqon A/S. QIAGEN also announced new plans to return $300 million of capital to shareholders by the end of 2017, expanding on the fourth $100 million share repurchase program announced in April 2016 (not yet initiated).

Click here for the full press release

Full press release including tables with detailed financial information can also be downloaded in PDF format from: https://www.qiagen.com/~/media/5a4500e7fb5047cf86d423ff45fa74f1.ashx

Investor Relations:
John Gilardi
Vice President Corporate Communications and Investor Relations
+49-2103-29-11711
+1-240-686-2222

Dr. Sarah Fakih
Associate Director Investor Relations
+49-2103-29-11457
Email: ir@qiagen.com
ir.qiagen.com